Siglec-4a/MAG, His, Human
| $340.00 | |
| Z05823-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| $340.00 | |
| Z05823-100 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 55.8 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 75-82 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS, 100mM L-arginine (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized Siglec-4a/MAG, His, Human, His Tag at 1 μg /ml(100 μl/well) on the plate. Dose response curve for Anti-Siglec-4a Antibody, hFc Tag with the EC50 of 2.4ng/ml determined by ELISA. »
The purity of Siglec-4a/MAG, His, Human is greater than 95% as determined by SEC-HPLC. »
Siglec-4a/MAG, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Siglec-4a, also known as Myelin-Associated Glycoprotein (MAG), is a type I transmembrane glycoprotein belonging to the Siglec family, a subgroup of the Ig superfamily. Adhesion molecule that mediates interactions between myelinating cells and neurons by binding to neuronal sialic acid-containing gangliosides and to the glycoproteins RTN4R and RTN4RL2. |
| Synonyms | MAG; Siglec4a; Siglec-4a; S-MAG; GMA |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.